<DOC>
	<DOCNO>NCT00600262</DOCNO>
	<brief_summary>Background : evaluate 3-month efficacy single dose intravitreal bevacizumab progression severe non proliferative diabetic retinopathy , proliferative diabetic retinopathy active photocoagulated diabetic proliferative evaluation ischemic area regression retinal disc neovasculrization . Methods : 40 patient enrol prospective , interventional study . Patients treat intravitreal bevacizumab 0.1ml ( 0.25mg ) . We evaluate visual acuity , neovascularization leakage point , capillary closure ischemic area macular edema clinical examination fluorescein angiography . A clinical examination perform baseline day 1,14 30 . Active leakage point measure fluorescein angiography 30 day .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Severe nonproliferative Proliferative diabetic retinopathy Active photocoagulated diabetic retinopathy Previous vascular occlusion Glaucoma Uncontrolled hypertension , thromboembolic event Renal abnormality Recent plan surgery Coagulation abnormalities Panretinal photocoagulation le one month Patients know serious allergy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>severe nonproliferative</keyword>
	<keyword>proliferative diabetic retinopathy</keyword>
	<keyword>active photocoagulated diabetic retinopathy</keyword>
	<keyword>intravitreal bevacizumab</keyword>
</DOC>